{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:22:11Z","timestamp":1783430531267,"version":"3.54.6"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T00:00:00Z","timestamp":1466380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Institute on Aging and the National Institute of Mental Health","award":["R01 AG031248"],"award-info":[{"award-number":["R01 AG031248"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim was to determine the relationship between (R) and (S)\u2010citalopram enantiomer exposure (AUC(0,24\u00a0h)) and therapeutic response in agitated individuals greater than 60 years old with Alzheimer's dementia (AD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Citalopram enantiomer exposures (AUC(0,24\u00a0h)) derived from an established population pharmacokinetic analysis were utilized to explore the relationship between (R)\u2010 and (S)\u2010citalopram area under the curve (AUC(0,24\u00a0)) and Mini\u2010Mental State Examination (MMSE), Neurobehavioural Rating Scale\u2010Agitation Subscale (NBRS\u2010A), modified Alzheimer's Disease Cooperative Study\u2010Clinical Global Impression of Change (mADCS\u2010CGIC) and Neuropsychiatric Inventory Agitation subscale (NPIA) scores. Time dependent changes in these scores (disease progression) were accounted for prior to exploring the exposure effect relationship for each enantiomer. These relationships were evaluated using a non\u2010linear\u2010mixed effects modelling approach as implemented in <jats:sc>nonmem<\/jats:sc> v7.3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>(S)\u2010AUC(0,24\u00a0h) and (R)\u2010AUC(0,24\u00a0h) each contributed to improvement in NBRS\u2010A scores (k3(R) \u22120.502; k4(S) \u22120.712) as did time in treatment. However, increasing (R)\u2010AUC(0,24\u00a0h) decreased the probability of patient response (maximum \u0394 \u22120.182%\/AUC(0,24\u00a0h)) based on the CGIC while (S)\u2010AUC(0,24\u00a0h) improved the probability of response (maximum \u0394 0.112%\/AUC(0,24\u00a0h)). (R)\u2010AUC(0,24\u00a0h) was also associated with worsening in MMSE scores (\u22120.5 points).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results suggest that citalopram enantiomers contributed differentially to treatment outcomes. (R)\u2010citalopram accounted for a greater proportion of the adverse consequences associated with racemic citalopram treatment in patients with AD including a decreased probability of treatment response as measured by the CGIC and a reduction in MMSE scores. The S\u2010enantiomer was associated with increased probability of response based on the CGIC.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12997","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T22:02:58Z","timestamp":1462399378000},"page":"784-792","source":"Crossref","is-referenced-by-count":37,"title":["R\u2010 and S\u2010citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation"],"prefix":"10.1111","volume":"82","author":[{"given":"Thang","family":"Ho","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology Indiana University School of Medicine  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Pollock","sequence":"additional","affiliation":[{"name":"Campbell Family Mental Health Research Institute CAMH, University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit H.","family":"Mulsant","sequence":"additional","affiliation":[{"name":"Campbell Family Mental Health Research Institute CAMH, University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schantz","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology Indiana University School of Medicine  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devangere P.","family":"Devanand","sequence":"additional","affiliation":[{"name":"Division of Geriatric Psychiatry, Colleges of Physicians and Surgeons Columbia University  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo E.","family":"Mintzer","sequence":"additional","affiliation":[{"name":"Clinical Biotechnology Research Institute Roper St. Francis Healthcare  Charleston South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton P.","family":"Porsteinsson","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Care, Research and Education Program (AD\u2010CARE) University of Rochester School of Medicine and Dentistry  Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon S.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Science, Keck School of Medicine University of Southern California  California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Perelman School of Medicine at the University of Pennsylvania  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Yesavage","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine  Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea T.","family":"Drye","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Johns Hopkins Bloomberg School of Public Health  Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Munro","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Department of Neurology Johns Hopkins Bayview and Johns Hopkins School of Medicine  Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Shade","sequence":"additional","affiliation":[{"name":"Department of Medicine (Pulmonary) and Epidemiology (Center for Clinical Trials) Johns Hopkins Bloomberg School of Public Health  Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Lyketsos","sequence":"additional","affiliation":[{"name":"Memory and Alzheimer's Treatment Center Johns Hopkins Bayview and Johns Hopkins School of Medicine  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bies","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology Indiana University School of Medicine  Indianapolis Indiana USA"},{"name":"Campbell Family Mental Health Research Institute CAMH, University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1204629"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1858"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.12.001"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1934"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1926"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.3.460"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3180cc1ff5"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.93"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.10.024"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565160-00013"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.08.008"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2006.pto_295.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32832a8ec8"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03891.x"},{"key":"e_1_2_9_18_1","first-page":"109","article-title":"Plasma levels of citalopram enantiomers and metabolites in elderly patients","volume":"33","author":"Foglia JP","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_9_19_1","first-page":"99","article-title":"A population pharmacokinetic model for R\u2010and S\u2010citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation","volume":"43","author":"Akil A","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"e_1_2_9_20_1","volume-title":"NONMEM users guide: introduction to NONMEM 7.3.0","author":"Bauer RJ","year":"2014"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02294361"},{"key":"e_1_2_9_22_1","volume-title":"Categorical Data Analysis","author":"Agresti A","year":"2013"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1865-z"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12997","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12997","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12997","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.12997","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T17:18:44Z","timestamp":1694366324000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,20]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/bcp.12997"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12997","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,20]]}}}